Wide Ranks

CCCC

C4 Therapeutics, Inc.

4.55

Top Statistics
Market Cap 321 M Forward PE -5.11 Revenue Growth 38.70 %
Current Ratio 6.31 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.15 Enterprise / Revenue 3.94 Price To Sales Trailing12 Months 9.54
Profitability
Profit Margins 0.00 % Operating Margins -183.86 %
Balance Sheet
Total Cash 255 M Total Cash Per Share 3.62 Total Debt 67 M
Total Debt To Equity 27.65 Current Ratio 6.31 Book Value Per Share 3.44
All Measures
Short Ratio 836.00 % Message Board Id finmb_321572356 Shares Short Prior Month 6 M
Return On Equity -0.4600 City Watertown Uuid b41c1949-bef0-3b7c-8399-8d0a5d83bcc2
Previous Close 4.19 First Trade Date Epoch Utc 1 B Book Value 3.44
Beta 3.06 Total Debt 67 M Volume 1 M
Price To Book 1.32 Fifty Two Week Low 1.06 Total Cash Per Share 3.62
Total Revenue 33 M Shares Short Previous Month Date 1 B Target Median Price 10.00
Audit Risk 2 Max Age 86400 Recommendation Mean 2.00
Sand P52 Week Change 0.3133 Operating Margins -183.86 % Target Mean Price 13.78
Net Income To Common -105497000 Short Percent Of Float 0.1270 Implied Shares Outstanding 70 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M
Average Volume10days 1 M Total Cash 255 M Next Fiscal Year End 1 B
Revenue Per Share 0.5220 Held Percent Insiders 0.1144 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 8
Regular Market Previous Close 4.19 Target Low Price 4.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 5.56 Open 4.23 Free Cashflow -41839376
State MA Dividend Yield 0.00 % Return On Assets -0.2061
Time Zone Short Name EST Board Risk 6 Trailing Eps -1.71
Day Low 4.23 Address1 490 Arsenal Way Shares Outstanding 70 M
Compensation Risk 10 Price Hint 4 Target High Price 39.00
Website https://www.c4therapeutics.com 52 Week Change 1.79 Average Volume 1 M
Forward Eps -1.71 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 614.40 % Is_sp_500 False Regular Market Day High 4.65
Profit Margins 0.00 % Debt To Equity 27.65 Fifty Two Week High 11.88
Day High 4.65 Shares Short 7 M Regular Market Open 4.23
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 3.94
Revenue Growth 38.70 % Shares Percent Shares Out 0.1049 Operating Cashflow -71234000
Currency USD Time Zone Full Name America/New_York Market Cap 321 M
Is_nasdaq_100 False Zip 02472 Quote Type EQUITY
Industry Biotechnology Long Name C4 Therapeutics, Inc. Overall Risk 8
Regular Market Day Low 4.23 Held Percent Institutions 0.9165 Current Price 4.55
Address2 Suite120 Enterprise To Ebitda -1.15 Financial Currency USD
Current Ratio 6.31 Gross Margins -222.31 % Industry Disp Biotechnology
Number Of Analyst Opinions 9 Country United States Float Shares 54 M
Two Hundred Day Average 6.38 Governance Epoch Date 1 B Enterprise Value 132 M
Price To Sales Trailing12 Months 9.54 Forward PE -5.11 Regular Market Volume 1 M
Ebitda -115127000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases.

Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.

The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC.

It has strategic collaborations with F.

Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co.

, Ltd.

; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC.

The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.